Bengt Wahlin1,2, Lena Innala3,4, Staffan Magnusson3,4, Bozena Möller3,4, Torgny Smedby3,4, Solbritt Rantapää-Dahlqvist3,4, Solveig Wållberg-Jonsson3,4. 1. From the Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå; Department of Rheumatology, Sundsvall Hospital, Sundsvall; Department of Rheumatology, Sunderby Hospital, Luleå; Department of Rheumatology, Östersund Hospital, Östersund, Sweden. bengt.wahlin@umu.se. 2. B. Wahlin, MD, PhD student, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University; L. Innala, MD, PhD, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University; S. Magnusson, MD, Department of Rheumatology, Sundsvall Hospital; B. Möller, MD, Department of Rheumatology, Sunderby Hospital; T. Smedby, MD, Department of Rheumatology, Östersund Hospital; S. Rantapää-Dahlqvist, MD, PhD, Professor, Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå; S. Wållberg-Jonsson, MD, PhD, Professor, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University. bengt.wahlin@umu.se. 3. From the Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå; Department of Rheumatology, Sundsvall Hospital, Sundsvall; Department of Rheumatology, Sunderby Hospital, Luleå; Department of Rheumatology, Östersund Hospital, Östersund, Sweden. 4. B. Wahlin, MD, PhD student, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University; L. Innala, MD, PhD, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University; S. Magnusson, MD, Department of Rheumatology, Sundsvall Hospital; B. Möller, MD, Department of Rheumatology, Sunderby Hospital; T. Smedby, MD, Department of Rheumatology, Östersund Hospital; S. Rantapää-Dahlqvist, MD, PhD, Professor, Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå; S. Wållberg-Jonsson, MD, PhD, Professor, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University.
Abstract
OBJECTIVE: Cardiovascular (CV) risk estimation calculators for the general population do not perform well in patients with rheumatoid arthritis (RA). An RA-specific risk calculator has been developed, but did not perform better than a risk calculator for the general population when validated in a heterogeneous multinational cohort. METHODS: In a cohort of patients with new-onset RA from northern Sweden (n = 665), the risk of CV disease was estimated by the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) and the American College of Cardiology/American Heart Association algorithm (ACC/AHA). The ACC/AHA estimation was analyzed, both as crude data and when adjusted according to the recommendations by the European League Against Rheumatism (ACC/AHA × 1.5). ERS-RA was calculated using 2 variants: 1 from patient and physician reports of hypertension (HTN) and hyperlipidemia [ERS-RA (reported)] and 1 from assessments of blood pressure (BP) and blood lipids [ERS-RA (measured)]. The estimations were compared with observed CV events. RESULTS: All variants of risk calculators underestimated the CV risk. Discrimination was good for all risk calculators studied. Performance of all risk calculators was poorer in patients with a high grade of inflammation, whereas ACC/AHA × 1.5 performed best in the high-inflammatory patients. In those patients with an estimated risk of 5-15%, no risk calculator performed well. CONCLUSION: ERS-RA underestimated the risk of a CV event in our cohort of patients, especially when risk estimations were based on patient or physician reports of HTN and hyperlipidemia instead of assessment of BP and blood lipids. The performance of ERS-RA was no better than that of ACC/AHA × 1.5, and neither performed well in high-inflammatory patients.
OBJECTIVE: Cardiovascular (CV) risk estimation calculators for the general population do not perform well in patients with rheumatoid arthritis (RA). An RA-specific risk calculator has been developed, but did not perform better than a risk calculator for the general population when validated in a heterogeneous multinational cohort. METHODS: In a cohort of patients with new-onset RA from northern Sweden (n = 665), the risk of CV disease was estimated by the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) and the American College of Cardiology/American Heart Association algorithm (ACC/AHA). The ACC/AHA estimation was analyzed, both as crude data and when adjusted according to the recommendations by the European League Against Rheumatism (ACC/AHA × 1.5). ERS-RA was calculated using 2 variants: 1 from patient and physician reports of hypertension (HTN) and hyperlipidemia [ERS-RA (reported)] and 1 from assessments of blood pressure (BP) and blood lipids [ERS-RA (measured)]. The estimations were compared with observed CV events. RESULTS: All variants of risk calculators underestimated the CV risk. Discrimination was good for all risk calculators studied. Performance of all risk calculators was poorer in patients with a high grade of inflammation, whereas ACC/AHA × 1.5 performed best in the high-inflammatory patients. In those patients with an estimated risk of 5-15%, no risk calculator performed well. CONCLUSION: ERS-RA underestimated the risk of a CV event in our cohort of patients, especially when risk estimations were based on patient or physician reports of HTN and hyperlipidemia instead of assessment of BP and blood lipids. The performance of ERS-RA was no better than that of ACC/AHA × 1.5, and neither performed well in high-inflammatory patients.
Authors: Ankush Jamthikar; Deep Gupta; Luca Saba; Narendra N Khanna; Tadashi Araki; Klaudija Viskovic; Sophie Mavrogeni; John R Laird; Gyan Pareek; Martin Miner; Petros P Sfikakis; Athanasios Protogerou; Vijay Viswanathan; Aditya Sharma; Andrew Nicolaides; George D Kitas; Jasjit S Suri Journal: Cardiovasc Diagn Ther Date: 2020-08
Authors: Lotta Ljung; Peter Ueda; Katherine P Liao; Jeffrey D Greenberg; Carol J Etzel; Daniel H Solomon; Johan Askling Journal: RMD Open Date: 2018-12-16
Authors: Panagiota Anyfanti; Athanasia Dara; Elena Angeloudi; Eleni Bekiari; Theodoros Dimitroulas; George D Kitas Journal: J Inflamm Res Date: 2021-12-14
Authors: Ankush D Jamthikar; Deep Gupta; Anudeep Puvvula; Amer M Johri; Narendra N Khanna; Luca Saba; Sophie Mavrogeni; John R Laird; Gyan Pareek; Martin Miner; Petros P Sfikakis; Athanasios Protogerou; George D Kitas; Raghu Kolluri; Aditya M Sharma; Vijay Viswanathan; Vijay S Rathore; Jasjit S Suri Journal: Rheumatol Int Date: 2020-08-28 Impact factor: 2.631